Your browser doesn't support javascript.
loading
Comprehensive Management of Renal Masses in Solitary Kidneys.
Yasuda, Yosuke; Zhang, Jj H; Attawettayanon, Worapat; Rathi, Nityam; Wilkins, Lamont; Roversi, Gustavo; Zhang, Ao; Accioly, Joao Pedro Emrich; Shah, Snehi; Munoz-Lopez, Carlos; Palacios, Diego Aguilar; Hofmann, Martin; Campbell, Rebecca A; Kaouk, Jihad; Haber, Georges-Pascal; Eltemamy, Mohamad; Krishnamurthi, Venkatesh; Abouassaly, Robert; Martin, Charles; Li, Jianbo; Weight, Christopher; Campbell, Steven C.
Affiliation
  • Yasuda Y; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA; Tokyo Medical and Dental University, Graduate School, Tokyo, Japan.
  • Zhang JH; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA; Institute of Urologic Oncology, Department of Urology, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
  • Attawettayanon W; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA; Division of Urology, Department of Surgery, Faculty of Medicine, Songklanagarind Hospital, Prince of Songkla University, Songkhla, Thailand.
  • Rathi N; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Wilkins L; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Roversi G; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Zhang A; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Accioly JPE; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Shah S; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Munoz-Lopez C; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Palacios DA; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Hofmann M; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Campbell RA; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Kaouk J; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Haber GP; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Eltemamy M; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Krishnamurthi V; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Abouassaly R; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Martin C; Interventional Radiology, Cleveland Clinic, Cleveland, OH, USA.
  • Li J; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
  • Weight C; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Campbell SC; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address: campbes3@ccf.org.
Eur Urol Oncol ; 6(1): 84-94, 2023 02.
Article in En | MEDLINE | ID: mdl-36517406
ABSTRACT

BACKGROUND:

A renal mass in a solitary kidney (RMSK) has traditionally been managed with partial nephrectomy (PN), although radical nephrectomy (RN) is occasionally required. Most RMSK studies have focused on patients for whom PN was achieved.

OBJECTIVE:

To provide a comprehensive analysis of the management strategies/outcomes for an RMSK and address knowledge deficits regarding this challenging disorder. DESIGN, SETTING, AND

PARTICIPANTS:

A total of 1024 patients diagnosed with an RMSK (1975-2022) were retrospectively evaluated. Baseline characteristics and pathologic/functional/survival outcomes were analyzed. INTERVENTION PN/RN/cryoablation (CA)/active surveillance (AS). OUTCOME MEASUREMENTS AND STATISTICAL

ANALYSIS:

Functional outcomes, perioperative morbidity/mortality, and 5-yr recurrence-free survival (RFS) were evaluated. Kruskal-Wallis and chi-square tests were used to compare cohorts, and log-rank test and Cox proportional hazard model were used for survival analysis. RESULTS AND

LIMITATIONS:

Of 1024 patients, 842 underwent PN (82%), 102 CA (10%), 54 RN (5%), and 26 AS (3%). The median tumor size and RENAL([R]adius [tumor size as maximal diameter], [E]xophytic/endophytic properties of tumor, [N]earness of tumor deepest portion to collecting system or sinus, [A]nterior [a]/posterior [p] descriptor, and [L]ocation relative to polar lines) score were 3.7 cm and 8, respectively. The median follow-up was 53 mo. For PN, 95% were clamped, and the median warm and cold ischemia times were 22 and 45 min, respectively. For PN, the median preoperative glomerular filtration rate (GFR) was 57 ml/min/1.73 m2, and the median new baseline and 5-yr GFRs were 47 and 48 ml/min/1.73 m2, respectively. Dialysis-free survival for PN was 97% at 5 yr. Twenty-two (2.1%) patients with clear-cell renal cell carcinoma and RENAL score ≥10 (median = 11) received tyrosine kinase inhibitors (TKIs) to facilitate PN, leading to 57% median decrease of tumor volume; PN was accomplished in 20 (91%). Forty-one patients had planned RN (4.0%), most often due to severe pre-existing chronic kidney disease (CKD), and 13 were converted from PN to RN (1.5%). Clavien III-V perioperative complications were observed in 80 (8%) patients and 90-d mortality was 0.6%. Five-year RFS for PN, CA, and RN were 83%, 80%, and 72%, respectively (p = 0.03 for PN vs RN).

CONCLUSIONS:

Nephron-sparing approaches are feasible and successful in most RMSK patients. PN for an RMSK is often challenging but can be facilitated by selective use of TKIs. RN is occasionally required due to severe CKD, over-riding oncologic concerns, or conversion from PN. This is the first large RMSK study to provide a comprehensive analysis of all management strategies/outcomes. PATIENT

SUMMARY:

Kidney cancer in a solitary kidney is a major challenge for achieving cancer-free status and avoiding dialysis. Although partial nephrectomy is the principal treatment for a renal mass in a solitary kidney, other options are occasionally required to optimize outcomes.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Renal Insufficiency, Chronic / Solitary Kidney / Kidney Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Eur Urol Oncol Year: 2023 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Renal Insufficiency, Chronic / Solitary Kidney / Kidney Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Eur Urol Oncol Year: 2023 Document type: Article Affiliation country: